BUZZ – Jefferies positive on CSL in near – term, sees growth in plasma industry01 Feb 2021 14:48
- * Jefferies is positive on drugmaker CSL in near-term, as it foresees growth in plasma industry and notes co's margins in industry about one-third higher than peers
- * Says only 20% of total potential patients in U.S and EU are receiving plasma treatment for most penetrated of base and specialty products, implying CSL and industry can continue to grow strongly
- * Jefferies also says co's Q2 projected earnings in U.S bodes well for its H1 FY21 margin
- * Brokerage uses data from IQVIA Health, a healthcare information and technology firm, which says that in 2QFY21, U.S. plasma product revenue increased by 9.5%, with high-margin specialty products up 18%
- * Notes U.S. flu vaccine revenue decreased by 7%, according to IQVIA, but higher-margin Fluad Quad sales now comprise about 40% of total flu vaccine sales - which may lead to higher margins in first-half
- * Sees 9% growth for CSL's high margin specialty product franchise in FY21
(Reporting by Arundhati Dutta in Bengaluru) (([email protected]
Jefferies positive on CSL in near-term, sees growth in plasma industry
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$260.88 |
Change
-4.650(1.75%) |
Mkt cap ! $126.3B | |||
| Open | High | Low | Value | Volume |
| $263.90 | $265.00 | $260.88 | $240.8M | 916.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 69 | $260.86 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $261.00 | 1249 | 1 |
View Market Depth
| Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
| CSL (ASX) Chart |